Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 270

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia: A Randomized Controlled Trial

Stein, Evan A., Illingworth, D. Roger, Kwiterovich, Jr, Peter O., Liacouras, Chris A., Siimes, Martti A., Jacobson, Marc S., Brewster, Thomas G., Hopkins, Paul, Davidson, Michael, Graham, Kevin, Arensman, Frederick, Knopp, Robert H., DuJovne, Carlos, Williams, Christine L., Isaacsohn, Jonathan L., Jacobsen, Carol A., Laskarzewski, Peter M., Ames, Sharon, Gormley, Glenn J.·1999·JAMA

Abstract

CONTEXT: Heterozygous familial hypercholesterolemia (HeFH) is a common disorder associated with early coronary artery disease, especially in men. The age at which drug therapy should be started is still controversial, as is the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). OBJECTIVE: To assess the lipid-lowering efficacy, biochemical safety, and effect on growth and sexual development of lovastatin in adolescent boys with HeFH. DESIGN: One-year, double-blind, placebo-controlled, balanced, 2-period, 2-arm randomized trial. In the first period (24 weeks), lovastatin was increased at 8 and 16 weeks and the dosage remained stable during the second period (24 weeks). The study was conducted between 1990 and 1994. SETTING: Fourteen pediatric outpatient clinics in the United States and Finland. PATIENTS: Boys aged 10 to 17 years with HeFH. Of 132 randomized subjects (67 intervention, 65 placebo), 122 (63 intervention, 59 placebo) and 110 (61 intervention, 49 placebo) completed the first and second periods, respectively. INTERVENTION: Lovastatin, starting at 10 mg/d, with a forced titration at 8 and 16 weeks to 20 and 40 mg/d, respectively, or placebo. MAIN OUTCOME MEASURES: The primary efficacy outcome measure was low-density lipoprotein cholesterol (LDL-C). Primary safety measures were growth and sexual development. RESULTS: Compared with placebo, LDL-C levels of patients receiving lovastatin decreased significantly (P<.001) by 17%, 24%, and 27% receiving dosages of 10, 20, and 40 mg/d, respectively, and remained 25 % lower than baseline at 48 weeks. Growth and sexual maturation assessed by Tanner staging and testicular volume were not significantly different between the lovastatin and placebo groups at 24 weeks (P = .85) and 48 weeks (P = .33); neither were serum hormone levels or biochemical parameters of nutrition. However, the study was underpowered to detect significant differences in safety parameters. Serum vitamin E levels were reduced with lovastatin treatment consistent with reductions in LDL-C, the major carrier of vitamin E in the circulation. CONCLUSIONS: This study in adolescent boys with HeFH confirmed the LDL-C-reducing effectiveness of lovastatin. Comprehensive clinical and biochemical data on growth, hormonal, and nutritional status indicated no significant differences between lovastatin and placebo over 48 weeks, although further study is required.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.281.2.137

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 270

Metadata

Authors
Stein, E. A., Illingworth, D. R., Kwiterovich, Jr., Liacouras, C. A., Siimes, M. A., Jacobson, M. S., Brewster, T. G., Hopkins, P., Davidson, M., Graham, K., Arensman, F., Knopp, R. H., DuJovne, C., Williams, C. L., Isaacsohn, J. L., Jacobsen, C. A., Laskarzewski, P. M., Ames, S., & Gormley, G. J.
Venue
JAMA
Published
1999-01-13
Volume
281
Issue
2
Pages
137
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2125639599
Cited by
270
References
41
FWCI
12.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1001/jama.281.2.137
The paper
Stein, E. A., Illingworth, D. R., Kwiterovich, Jr., Liacouras, C. A., Siimes, M. A., Jacobson, M. S., Brewster, T. G., Hopkins, P., Davidson, M., Graham, K., Arensman, F., Knopp, R. H., DuJovne, C., Williams, C. L., Isaacsohn, J. L., Jacobsen, C. A., Laskarzewski, P. M., Ames, S., & Gormley, G. J. (1999). Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia: A Randomized Controlled Trial. JAMA. https://doi.org/10.1001/jama.281.2.137

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.